Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MDT stock price vs WAT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WAT's multiple
Needs WAT P/E.
Implied fair value · at MDT's multiple
Needs MDT P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
19 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Medtronic plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Waters Corporation · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Abbott Laboratories
MDT vs ABT
Johnson & Johnson
MDT vs JNJ
STRYKER CORP
MDT vs SYK
BECTON DICKINSON & CO
MDT vs BDX
DANAHER CORP /DE/
MDT vs DHR
AGILENT TECHNOLOGIES, INC.
MDT vs A
BIO-RAD LABORATORIES, INC.
MDT vs BIO
THERMO FISHER SCIENTIFIC INC.
MDT vs TMO
BRUKER CORP
MDT vs BRKR
BIO-TECHNE Corp
MDT vs TECH
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MDT can sustain mid-single-digit to high-single-digit growth while improving margins toward WAT levels, then accumulating MDT makes sense because its valuation is far below WAT on every major multiple; otherwise, the current price already sits near the top of MDT’s historical band and the upside case is less compelling.
MDT trades at a large discount to WAT on P/E, P/S, EV/EBITDA, and EV/Revenue, which points to meaningful upside if the market re-rates MDT toward WAT-like multiples. However, WAT’s stronger profitability and ROIC help explain why WAT commands a higher valuation.
Supporting Metrics
